Therapeutic approaches in hereditary angioedema

Area of Science:

• Immunology
• Genetics
• Pharmacology

Background:

• Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent, unpredictable swelling attacks.
• These attacks are linked to dysregulation of the kallikrein-kinin system, often due to C1-inhibitor (C1-INH) deficiency or dysfunction.
• Laryngeal angioedema presents a life-threatening risk during HAE attacks.

Purpose of the Study:

• To review currently available and emerging therapies for hereditary angioedema.
• To discuss the mechanisms of action for different HAE treatment options.
• To highlight the impact of these therapies on disease management and patient outcomes.

Main Methods:

• Literature review of approved and investigational therapies for HAE.
• Analysis of pharmacological agents targeting the kallikrein-kinin pathway.
• Synthesis of information on treatment efficacy and safety profiles.

Main Results:

• Several therapeutic agents are approved for HAE, including plasma-derived C1-INH, recombinant C1-INH, bradykinin receptor antagonists (e.g., icatibant), and kallikrein inhibitors (e.g., ecallantide).
• These therapies can be used for acute attack treatment or prophylaxis, with varying mechanisms of action.
• While not universally accessible, these treatments have significantly improved HAE management.

Conclusions:

• A growing number of targeted therapies are available for HAE, addressing both acute attacks and long-term prevention.
• The diverse mechanisms of action allow for tailored treatment strategies in HAE management.
• Continued research and development are crucial for expanding global access to effective HAE therapies.